EPZM - Epizyme, Inc.

Epizyme, Inc. (EPZM) is a clinical-stage biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other diseases. The company is headquartered in Cambridge, Massachusetts, and was founded in 2007.

Epizyme's lead product candidate is tazemetostat, an oral, small molecule inhibitor of the EZH2 enzyme. EZH2 is a histone methyltransferase that is frequently overexpressed in cancer and plays a role in tumor growth and progression. Tazemetostat is being developed for the treatment of a range of cancers, including non-Hodgkin lymphoma (NHL), solid tumors, and synovial sarcoma. The drug has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory follicular lymphoma.

In addition to tazemetostat, Epizyme is also developing a pipeline of novel inhibitors of other epigenetic targets. These targets include DOT1L, EZH1, and PRMT5, which are implicated in the development and progression of various types of cancer.

Epizyme has collaborations with several leading pharmaceutical companies, including Celgene, Eisai, and Genentech. These partnerships provide funding, as well as access to technology and expertise, to support the development of its pipeline.

The company's financials have been mixed, with increasing revenues in recent years but also significant losses. As of December 31, 2020, the company reported a net loss of $274.8 million for the year, primarily due to higher research and development expenses related to its clinical programs.

Overall, Epizyme's mission is to develop innovative therapies that have the potential to transform the lives of patients with cancer and other serious diseases. The company's focus on epigenetic targets represents a promising approach to addressing unmet medical needs and improving patient outcomes.